Thrombosis Research
Volume 121, Issue 3 , Pages 293-299 , 2007

Soluble CD40 ligand:interleukin-10 ratio predicts in-hospital adverse events in patients with ST-segment elevation myocardial infarction

  • Alberto Dominguez-Rodriguez

      Affiliations

    • Department of Cardiology (Coronary Care Unit), Hospital Universitario de Canarias, Tenerife, Spain
    • Corresponding Author InformationCorresponding author. Coronary Care Unit, University Hospital of Canarias, Ofra s/n La Cuesta E-38320, Tenerife, Spain. Tel.: +34 922 679030; fax: +34 922 362716.
    • ,
  • Pedro Abreu-Gonzalez

      Affiliations

    • Department of Physiology, University of La Laguna, School of Medicine, Tenerife, Spain
    • ,
  • Martín J. Garcia-Gonzalez

      Affiliations

    • Department of Cardiology (Coronary Care Unit), Hospital Universitario de Canarias, Tenerife, Spain
    • ,
  • Juan Carlos Kaski

      Affiliations

    • Cardiovascular Biology Research Centre, Division of Cardiac and Vascular Sciences, St. George's, University of London, London, United Kingdom

Received 5 March 2007 ,Revised 10 April 2007 ,Accepted 12 April 2007.

References 

  1. Ross R. Atherosclerotic: an inflammatory disease. N Engl J Med. 1999;340:115–126
  2. Lindmark E, Wallentin L, Siegbahn A. Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease. Thromb Res. 2001;103:249–259
  3. Lind L. Circulating markers of inflammation and atherosclerosis. Atherosclerosis. 2003;169:203–214
  4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–879
  5. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200–203
  6. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:4–43
  7. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–594
  8. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995;25:1749–1754
  9. Henn V, Steinbach S, Buchner K, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047–1054
  10. de Vries JE. Immunosuppressive and anti-inflammatory properties of interleukin-10. Ann Med. 1995;27:537–541
  11. Mills R, Bhatt DL. The Yin and Yang of arterial inflammation. J Am Coll Cardiol. 2004;44:50–52
  12. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–1111
  13. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Nuzzo R, et al. Soluble CD40L risk prediction after acute coronary syndromes. Circulation. 2003;108:1049–1052
  14. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, et al. Serum level of the antiinflamatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation. 2003;107:2109–2114
  15. Tziakas DN, Chalikias GK, Kaski JC, Kekes A, Hatzinikolaou EI, Stakos DA, Tentes IK, Kortsaris AX, Hatseras DI. Inflammatory and anti-inflammatory variable clusters and risk prediction in acute coronary syndrome patients: A factor analysis approach. Atherosclerosis in press.
  16. Chalikias GK, Tziakas DN, Kaski JC, Kekes A, Hatzinikolaou EI, Stakos DA, et al. Interleukin-18/interleukin-10 ratio is an independent predictor of recurrent coronary events during a 1-year follow-up in patients with acute coronary syndrome. Int J Cardiol. 2007;117:333–339
  17. Myocardial infarction redefined — a consensus of the Join European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. Eur Heart J. 2000;21:1502–1513
  18. Miller JM, Smalling R, Ohman EM, Bode C, Betriu A, Kleiman NS, et al. Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Am J Cardiol. 1999;84:779–784
  19. Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol. 1967;20:457–464
  20. Mahajan N, Mehta Y, Rose M, Shani J, Lichstein E. Elevated troponin level is not synonymous with myocardial infarction. Int J Cardiol. 2006;111:442–449
  21. Setsuta K, Seino Y, Takahashi N, Ogawa T, Sasaki K, Harada A, et al. Clinical significance of elevated levels of cardiac troponin T in patients with chronic heart failure. Am J Cardiol. 1999;84:608–611
  22. Hamm CW. Acute coronary syndromes. The diagnostic role of troponins. Thromb Res. 2001;103(Suppl 1):S63–S69
  23. Emond M, Mock MB, Davis KB, Fisher LD, Holmes DR, Chaitman BR, et al. Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) registry. Circulation. 1994;90:2645–2657
  24. Brezinski D, Stone PH, Muller JE, Tofler GH, Davis V, Parker C, et al. Prognostic significance of the Karnofsky performance status score in patients with acute myocardial infarction: comparison with the left ventricular ejection fraction and the exercise treadmill test performance. The MILIS study group. Am Heart J. 1991;121:1374–1381
  25. Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100:793–798
  26. Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396–399
  27. Urbich C, Mallat Z, Tedgui A, Clauss M, Zeiher AM, Dimmeler S. Upregulation of TRAF-3 by shear stress blocks CD40-mediated endothelial activation. J Clin Invest. 2001;108:1451–1458
  28. Andre P, Prasad KS, Denis CV, He M, Papalia JM, Hynes RO, et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med. 2002;8:247–252
  29. Mason PJ, Chakrabarti S, Albers AA, Rex S, Vitseva O, Varghese S, et al. Plasma, serum, and platelet expression of CD40 ligand in adults with cardiovascular disease. Am J Cardiol. 2005;96:1365–1369
  30. Perez Fernandez R, Kaski JC. Interleukin-10 and coronary disease. Rev Esp Cardiol. 2002;55:738–750
  31. Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, et al. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92:748–755
  32. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998–3002
  33. Waehre T, Halvorsen B, Damas JK, Yndestad A, Brosstad F, Gullestad L, et al. Inflammatory imbalance between IL-10 and TNF-α in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest. 2002;32:803–810
  34. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK, et al. Cross regulatory roles of interleukin-12 and interleukin-10 in atherosclerosis. J Clin Invest. 1996;97:2130–2138
  35. Chalikias GK, Tziakas DN, Kaski JC, Hatzinikolaou EI, Stakos DA, Tentes IK, et al. Interleukin-18: interleukin-10 ratio and in-hospital adverse events in patients with acute coronary syndrome. Atherosclerosis. 2005;182:135–143
  36. Kilic T, Ural D, Ural E, Yumuk Z, Agacdiken A, Sahin T, et al. Relation between proinflammatory to anti-inflammatory cytokine ratios and long-term prognosis in patients with non-ST elevation acute coronary syndrome. Heart. 2006;92:1041–1046

PII: S0049-3848(07)00178-8

doi: 10.1016/j.thromres.2007.04.007

Thrombosis Research
Volume 121, Issue 3 , Pages 293-299 , 2007

Article Tools

* Image Usage & Resolution